Our research goal is to determine the regulatory mechanisms controlling the function of Ewing sarcoma fusion proteins during induction of mitotic dysfunction, chromosomal instability (CIN), and ultimately in the pathogenesis of Ewing sarcoma, a pediatric bone cancer. Ewing sarcoma cells express aberrant EWS/FLI1 fusion protein, derived by chromosomal translocation, and this leads to impaired target gene expression through altered transcription and splicing. In addition to these mechanisms, we previously identified a novel function of EWS/FLI1 which leads to mitotic dysfunction through interaction with EWS and inhibition of EWS activity. Our study demonstrated that EWS regulates mitosis through interaction with Aurora B kinase (Aurora B), and through recruitment of Aurora B to the midzone, a midline structure that is located between segregating chromosomes. Disruption of EWS-Aurora B interaction by EWS/FLI1 protein may be a contributing factor in the development of Ewing sarcoma, because compromised Aurora B-relocation leads to defects in cytokinesis, missegregation of chromosomes, and ultimately, to induction of CIN. The mechanisms that modulate EWS/FLI1 activity during the induction of mitotic dysfunction and CIN are unknown. One possible regulatory mechanism is post-translational modification (PTM), and a previous study showed that EWS and EWS/FLI1 undergo O-GlcNAcylation, a form of PTM wherein a single ?-N- acetylglucosamine sugar is attached to Ser or Thr residues. We therefore chose to investigate O-GlcNAcylation as a potential regulatory mechanism for EWS/FLI1-dependent mitotic dysfunction. Our previous study demonstrated that elevated cellular O-GlcNAc levels induce midzone formation defects in HeLa cells. Because EWS forms homodimers, and EWS/FLI1 interaction with EWS disrupts its mitotic function, we hypothesize that O-GlcNAcylation of EWS/FLI1 induces midzone dysfunction by enabling the fusion protein to form a stable dimer with EWS. We will utilize an EWS/FLI1 construct containing a point mutation at the proposed critical O-GlcNAcylation site in human cells (HeLa and Ewing sarcoma A673 cells), to investigate our hypothesis, by addressing the following specific aim.
Specific Aim 1 : To determine how O-GlcNAcylation of EWS/FLI1 and EWS affects the induction of CIN. In addition to EWS/FLI1 in Ewing sarcoma, EWS is fused to different genes in other types of sarcomas, and the resulting EWS-fusion genes are thought to be responsible for transformation. The significance of this study is that impairment of mitosis by O-GlcNAcylation of EWS-fusion proteins may be a universal mechanism for pathogenesis in all sarcomas expressing EWS-fusion genes. Thus, our study may supply a platform for understanding the molecular mechanism regulating all EWS-fusion gene derived sarcomas. 1

Public Health Relevance

Ewing sarcoma is the second most common form of bone cancer in children. To understand how this cancer develops, we will study Ewing sarcoma EWS and EWS/FLI1 proteins during cell division using human cells. This study may have an impact on public health because it could lead to the discovery of diagnostic markers of cancer and drugs for patient therapy. PHS 398/2590 (Rev. 06/09) Page 1 Continuation Format Page

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
5R03CA223949-02
Application #
9608001
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Witkin, Keren L
Project Start
2017-12-05
Project End
2020-11-30
Budget Start
2018-12-01
Budget End
2020-11-30
Support Year
2
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Kansas Lawrence
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Cork, Gentry K; Thompson, Jeffrey; Slawson, Chad (2018) Real Talk: The Inter-play Between the mTOR, AMPK, and Hexosamine Biosynthetic Pathways in Cell Signaling. Front Endocrinol (Lausanne) 9:522
Slawson, Chad (2018) New ways of thinking about old things: the role of O-GlcNAc in cellular metabolism. J Bioenerg Biomembr 50:153-154